Dihydroartemisinin-piperaquine for the prevention of malaria in pregnancy

New England Journal of Medicine

Volumn 374, Issue 10, 2016, Pages 928-939

  Kakuru, Abel ^a   Jagannathan, Prasanna ^a   Muhindo, Mary K ^a   Natureeba, Paul ^b   Awori, Patricia ^b   Nakalembe, Miriam ^b   Opira, Bishop ^c   Olwoch, Peter ^d   Ategeka, John ^e   Nayebare, Patience ^c   Clark, Tamara D ^d   Feeney, Margaret E ^c   Charlebois, Edwin D ^e   Rizzuto, Gabrielle ^b   Muehlenbachs, Atis ^b   Havlir, Diane V ^a   Kamya, Moses R ^d   Dorsey, Grant ^f  

^a INFECTIOUS DISEASES RESEARCH COLLABORATION   (Uganda)

^b MAKERERE UNIVERSITY COLLEGE OF HEALTH SCIENCES   (Uganda)

^c Pediatrics   (Uganda)

^d Center for AIDS Prevention Studies   (Uganda)

^e SAN FRANCISCO GENERAL HOSPITAL   (United States)

^f NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIHYDROARTEMISININ PLUS PIPERAQUINE; PYRIMETHAMINE PLUS SULFADOXINE; ANTIMALARIAL AGENT; ARTEMISININ DERIVATIVE; DIHYDROARTEMISININ; DRUG COMBINATION; FANASIL, PYRIMETHAMINE DRUG COMBINATION; PIPERAQUINE; PYRIMETHAMINE; QUINOLINE DERIVATIVE; SULFADOXINE;

ABDOMINAL PAIN; ADOLESCENT; ADULT; ANEMIA; ANOREXIA; ARTICLE; CHILL; COMPARATIVE EFFECTIVENESS; CONGENITAL MALFORMATION; CONTROLLED STUDY; COUGHING; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DYSPHAGIA; FEMALE; HEADACHE; HISTOPATHOLOGY; HUMAN; HYPOTENSION; INCIDENCE; MAJOR CLINICAL STUDY; MALAISE; MALARIA CONTROL; NAUSEA; PARASITEMIA; PLACENTA MALARIA; PREECLAMPSIA; PREGNANCY OUTCOME; PREVALENCE; PRIORITY JOURNAL; PYELONEPHRITIS; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY DISTRESS; STILLBIRTH; URINARY TRACT INFECTION; VAGINA BLEEDING; VOMITING; CHEMICALLY INDUCED; DRUG ADMINISTRATION; DRUG COMBINATION; DRUG RESISTANCE; MALARIA; PREGNANCY; PREGNANCY COMPLICATIONS, PARASITIC; UGANDA; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIMALARIALS; ARTEMISININS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; DRUG RESISTANCE; FEMALE; HUMANS; INCIDENCE; MALARIA; PARASITEMIA; PREGNANCY; PREGNANCY COMPLICATIONS, PARASITIC; PREGNANCY OUTCOME; PYRIMETHAMINE; QUINOLINES; SULFADOXINE; UGANDA; VOMITING; YOUNG ADULT;

EID: 84960414013     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1509150     Document Type: Article

References (36)

1. Dellicour S, Tatem AJ, Guerra CA, Snow RW, ter Kuile FO. Quantifying the number of pregnancies at risk of malaria in 2007: A demographic study. PLoS Med 2010; 7(1): e1000221.
2. Steketee RW, Nahlen BL, Parise ME, Menendez C. The burden of malaria in pregnancy in malaria-endemic areas. Am J Trop Med Hyg 2001; 64: Suppl: 28-35.
3. Guyatt HL, Snow RW. The epidemiology and burden of Plasmodium falciparum-related anemia among pregnant women in sub-Saharan Africa. Am J Trop Med Hyg 2001; 64: Suppl: 36-44.
4. Updated WHO policy recommendation: intermittent preventive treatment of malaria in pregnancy using sulfadoxinepyrimethamine (IPTp-SP). Geneva: World Health Organization, 2012 (http://www.who .int/malaria/publications/atoz/who-iptp-sp-policy-recommendation/en/).
5. Schultz LJ, Steketee RW, Macheso A, Kazembe P, Chitsulo L, Wirima JJ. The efficacy of antimalarial regimens containing sulfadoxine-pyrimethamine and/or chloroquine in preventing peripheral and placental Plasmodium falciparum infection among pregnant women in Malawi. Am J Trop Med Hyg 1994; 51: 515-22.
6. Verhoeff FH, Brabin BJ, Chimsuku L, Kazembe P, Russell WB, Broadhead RL. An evaluation of the effects of intermittent sulfadoxine-pyrimethamine treatment in pregnancy on parasite clearance and risk of low birthweight in rural Malawi. Ann Trop Med Parasitol 1998; 92: 141-50.
7. Shulman CE, Dorman EK, Cutts F, et al. Intermittent sulphadoxine-pyrimethamine to prevent severe anaemia secondary to malaria in pregnancy: A randomised placebo-controlled trial. Lancet 1999; 353: 632-6.
8. Kayentao K, Kodio M, Newman RD, et al. Comparison of intermittent preventive treatment with chemoprophylaxis for the prevention of malaria during pregnancy in Mali. J Infect Dis 2005; 191: 109-16.
9. Naidoo I, Roper C. Drug resistance maps to guide intermittent preventive treatment of malaria in African infants. Parasitology 2011; 138: 1469-79.
10. Gutman J, Mwandama D, Wiegand RE, Ali D, Mathanga DP, Skarbinski J. Effectiveness of intermittent preventive treatment with sulfadoxine-pyrimethamine during pregnancy on maternal and birth outcomes in Machinga district, Malawi. J Infect Dis 2013; 208: 907-16.
11. Moussiliou A, De Tove YS-S, Doritchamou J, et al. High rates of parasite recrudescence following intermittent preventive treatment with sulphadoxine-pyrimethamine during pregnancy in Benin. Malar J 2013; 12: 195.
12. Arinaitwe E, Ades V, Walakira A, et al. Intermittent preventive therapy with sulfadoxine-pyrimethamine for malaria in pregnancy: A cross-sectional study from Tororo, Uganda. PLoS One 2013; 8(9): e73073.
13. Harrington WE, Mutabingwa TK, Kabyemela E, Fried M, Duffy PE. Intermittent treatment to prevent pregnancy malaria does not confer benefit in an area of widespread drug resistance. Clin Infect Dis 2011; 53: 224-30.
14. Clerk CA, Bruce J, Affipunguh PK, et al. A randomized, controlled trial of intermittent preventive treatment with sulfadoxine-pyrimethamine, amodiaquine, or the combination in pregnant women in Ghana. J Infect Dis 2008; 198: 1202-11.
15. Gonzez R, Mombo-Ngoma G, Ouraogo S, et al. Intermittent preventive treatment of malaria in pregnancy with mefloquine in HIV-negative women: A multicentre randomized controlled trial. PLoS Med 2014; 11(9): e1001733.
16. Piola P, Nabasumba C, Turyakira E, et al. Efficacy and safety of artemetherlumefantrine compared with quinine in pregnant women with uncomplicated Plasmodium falciparum malaria: An openlabel, randomised, non-inferiority trial. Lancet Infect Dis 2010; 10: 762-9.
17. Rijken MJ, McGready R, Boel ME, et al. Dihydroartemisinin-piperaquine rescue treatment of multidrug-resistant Plasmodium falciparum malaria in pregnancy: A preliminary report. Am J Trop Med Hyg 2008; 78: 543-5.
18. White NJ. Intermittent presumptive treatment for malaria. PLoS Med 2005; 2(1): e3.
19. Kamya MR, Arinaitwe E, Wanzira H, et al. Malaria transmission, infection, and disease at three sites with varied transmission intensity in Uganda: implications for malaria control. Am J Trop Med Hyg 2015; 92: 903-12.
20. Division of AIDS (DAIDS) table for grading the severity of adult and pediatric adverse events. Version 2.0. Washington, DC: Department of Health and Human Services, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Division of AIDS, 2014 (http://rsc .tech-res .com/Document/safetyand pharmacovigilance/DAIDS-AE-Grading Table-v2-NOV2014.pdf).
21. Hopkins H, Gonzez IJ, Polley SD, et al. Highly sensitive detection of malaria parasitemia in a malaria-endemic setting: performance of a new loop-mediated isothermal amplification kit in a remote clinic in Uganda. J Infect Dis 2013; 208: 645-52.
22. Natureeba P, Ades V, Luwedde F, et al. Lopinavir/ritonavir-based antiretroviral treatment (ART) versus efavirenz-based ART for the prevention of malaria among HIV-infected pregnant women. J Infect Dis 2014; 210: 1938-45.
23. Rogerson SJ, Hviid L, Duffy PE, Leke RFG, Taylor DW. Malaria in pregnancy: pathogenesis and immunity. Lancet Infect Dis 2007; 7: 105-17.
24. Muehlenbachs A, Fried M, McGready R, et al. A novel histological grading scheme for placental malaria applied in areas of high and low malaria transmission. J Infect Dis 2010; 202: 1608-16.
25. Mbonye AK, Birungi J, Yanow SK, et al. Prevalence of Plasmodium falciparum resistance markers to sulfadoxine-pyrimethamine among pregnant women receiving intermittent preventive treatment for malaria in Uganda. Antimicrob Agents Chemother 2015; 59: 5475-82.
26. Matondo SI, Temba GS, Kavishe AA, et al. High levels of sulphadoxine-pyrimethamine resistance Pfdhfr-Pfdhps quintuple mutations: A cross sectional survey of six regions in Tanzania. Malar J 2014; 13: 152.
27. Bertin G, Briand V, Bonaventure D, et al. Molecular markers of resistance to sulphadoxine-pyrimethamine during intermittent preventive treatment of pregnant women in Benin. Malar J 2011; 10: 196.
28. Bigira V, Kapisi J, Clark TD, et al. Protective efficacy and safety of three antimalarial regimens for the prevention of malaria in young Ugandan children: A randomized controlled trial. PLoS Med 2014; 11(8): e1001689.
29. Zani B, Gathu M, Donegan S, Olliaro PL, Sinclair D. Dihydroartemisinin-piperaquine for treating uncomplicated Plasmodium falciparum malaria. Cochrane Database Syst Rev 2014; 1: CD010927.
30. Poespoprodjo JR, Fobia W, Kenangalem E, et al. Dihydroartemisinin-piperaquine treatment of multidrug resistant falciparum and vivax malaria in pregnancy. PLoS One 2014; 9(1): e84976.
31. Lwin KM, Phyo AP, Tarning J, et al. Randomized, double-blind, placebo-controlled trial of monthly versus bimonthly dihydroartemisinin-piperaquine chemoprevention in adults at high risk of malaria. Antimicrob Agents Chemother 2012; 56: 1571-7.
32. Desai M, Gutman J, Llanziva A, et al. Intermittent screening and treatment or intermittent preventive treatment with dihydroartemisinin-piperaquine versus intermittent preventive treatment with sulfadoxine-pyrimethamine for the control of malaria during pregnancy in western Kenya: An open-label, three-group, randomised controlled superiority trial. Lancet 2015; 386: 2507-19.
33. Cottrell G, Moussiliou A, Luty AJ, et al. Submicroscopic Plasmodium falciparum infections are associated with maternal anemia, premature births, and low birth weight. Clin Infect Dis 2015; 60: 1481-8.
34. Cohee LM, Kalilani-Phiri L, Boudova S, et al. Submicroscopic malaria infection during pregnancy and the impact of intermittent preventive treatment. Malar J 2014; 13: 274.
35. Nankabirwa JI, Wandera B, Amuge P, et al. Impact of intermittent preventive treatment with dihydroartemisinin-piperaquine on malaria in Ugandan schoolchildren: A randomized, placebo-controlled trial. Clin Infect Dis 2014; 58: 1404-12.
36. European Medicines Agency. Eurartesim. 2013 (http://www.ema .europa .eu/ema/index .jsp?curl=pages/medicines/human/medicines/001199/human-med-001450 .jsp&murl=menus/medicines/medicines .jsp&mid=WC0b01ac058001d124&jsenabled =true).